Table 2.

Multivariable regression models for objective assessment and TDM performance in the 12 weeks prior to therapy change (either dose change or discontinuation)

	At least one objective assessmenta			TDM performed
	OR	95% CI	p value	OR	95% CI	p value
Sex (female vs. male)	0.849	0.565–1.274	0.4283	1.480	0.929–2.361	0.0993
Race (white vs. nonwhite)	0.657	0.330–1.306	0.2305	1.152	0.540–2.456	0.7147
Age at therapy change (years)	1.004	0.989–1.019	0.6215	0.996	0.979–1.013	0.6164
Previous biologic use (yes vs. no)	1.027	0.639–1.652	0.9120	0.980	0.5840–1.642	0.9378
Disease duration at therapy change (years)	0.987	0.964–1.011	0.2896	0.997	0.969–1.025	0.8133
Site type (academic vs. community)	1.588	1.010–2.495	0.0452	1.114	0.662–1.875	0.6845
Private insurance at enrollment (yes vs. no)	1.044	0.602–1.811	0.8781	1.188	0.626–2.253	0.5979
Drug classb			0.0083
Adalimumab	Ref	Ref	–	Ref	Ref	Ref
Infliximab	0.569	0.360–0.900	0.0159	0.844	0.529–1.348	0.4779
Other anti-TNF	1.460	0.576–3.705	0.4252
Ustekinumab	0.353	0.137–0.914	0.0320
Vedolizumab	1.359	0.683–2.702	0.3819
Disease type (CD vs. UC)	1.181	0.734–1.901	0.4923	0.953	0.567–1.602	0.8566
Therapy change (discontinuation vs. dose change)	1.178	0.776–1.788	0.4417	1.011	0.634–1.613	0.9632

^aObjective assessment included fecal calprotectin, C-reactive protein, endoscopy, MRI, or CT scan

^bFor TDM model, drug class compared infliximab to adalimumab (reference) as these were the only two biologics included in the TDM assessment population